27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression
Copyright © 2020 Elsevier B.V. All rights reserved..
Breast cancer remains one of the leading causes of cancer mortality in the US. Elevated cholesterol is a major risk factor for breast cancer onset and recurrence, while cholesterol-lowering drugs, such as statins, are associated with a good prognosis. Previous work in murine models showed that cholesterol increases breast cancer metastasis, and the pro-metastatic effects of cholesterol were due to its primary metabolite, 27-hydroxycholesterol (27HC). In our prior work, myeloid cells were found to be required for the pro-metastatic effects of 27HC, but their precise contribution remains unclear. Here we report that 27HC impairs T cell expansion and cytotoxic function through its actions on myeloid cells, including macrophages, in a Liver X receptor (LXR) dependent manner. Many oxysterols and LXR ligands had similar effects on T cell expansion. Moreover, their ability to induce the LXR target gene ABCA1 was associated with their effectiveness in impairing T cell expansion. Induction of T cell apoptosis was likely one mediator of this impairment. Interestingly, the enzyme responsible for the synthesis of 27HC, CYP27A1, is highly expressed in myeloid cells, suggesting that 27HC may have important autocrine or paracrine functions in these cells, a hypothesis supported by our finding that breast cancer metastasis was reduced in mice with a myeloid specific knockout of CYP27A1. Importantly, pharmacologic inhibition of CYP27A1 reduced metastatic growth and improved the efficacy of checkpoint inhibitor, anti-PD-L1. Taken together, our work suggests that targeting the CYP27A1 axis in myeloid cells may present therapeutic benefits and improve the response rate to immune therapies in breast cancer.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:493 |
|---|---|
| Enthalten in: |
Cancer letters - 493(2020) vom: 28. Nov., Seite 266-283 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Ma, Liqian [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 25.03.2021 Date Revised 29.11.2021 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.canlet.2020.08.020 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM314348484 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM314348484 | ||
| 003 | DE-627 | ||
| 005 | 20231225152533.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2020 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.canlet.2020.08.020 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1047.xml |
| 035 | |a (DE-627)NLM314348484 | ||
| 035 | |a (NLM)32861706 | ||
| 035 | |a (PII)S0304-3835(20)30435-3 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Ma, Liqian |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a 27-Hydroxycholesterol acts on myeloid immune cells to induce T cell dysfunction, promoting breast cancer progression |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 25.03.2021 | ||
| 500 | |a Date Revised 29.11.2021 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2020 Elsevier B.V. All rights reserved. | ||
| 520 | |a Breast cancer remains one of the leading causes of cancer mortality in the US. Elevated cholesterol is a major risk factor for breast cancer onset and recurrence, while cholesterol-lowering drugs, such as statins, are associated with a good prognosis. Previous work in murine models showed that cholesterol increases breast cancer metastasis, and the pro-metastatic effects of cholesterol were due to its primary metabolite, 27-hydroxycholesterol (27HC). In our prior work, myeloid cells were found to be required for the pro-metastatic effects of 27HC, but their precise contribution remains unclear. Here we report that 27HC impairs T cell expansion and cytotoxic function through its actions on myeloid cells, including macrophages, in a Liver X receptor (LXR) dependent manner. Many oxysterols and LXR ligands had similar effects on T cell expansion. Moreover, their ability to induce the LXR target gene ABCA1 was associated with their effectiveness in impairing T cell expansion. Induction of T cell apoptosis was likely one mediator of this impairment. Interestingly, the enzyme responsible for the synthesis of 27HC, CYP27A1, is highly expressed in myeloid cells, suggesting that 27HC may have important autocrine or paracrine functions in these cells, a hypothesis supported by our finding that breast cancer metastasis was reduced in mice with a myeloid specific knockout of CYP27A1. Importantly, pharmacologic inhibition of CYP27A1 reduced metastatic growth and improved the efficacy of checkpoint inhibitor, anti-PD-L1. Taken together, our work suggests that targeting the CYP27A1 axis in myeloid cells may present therapeutic benefits and improve the response rate to immune therapies in breast cancer | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Research Support, U.S. Gov't, Non-P.H.S. | |
| 650 | 4 | |a 27-Hydroxycholesterol | |
| 650 | 4 | |a Breast cancer | |
| 650 | 4 | |a Cholesterol | |
| 650 | 4 | |a Immune suppression | |
| 650 | 4 | |a Macrophage | |
| 650 | 4 | |a Myeloid cell | |
| 650 | 4 | |a T cell | |
| 650 | 7 | |a ABCA1 protein, human |2 NLM | |
| 650 | 7 | |a ATP Binding Cassette Transporter 1 |2 NLM | |
| 650 | 7 | |a Hydroxycholesterols |2 NLM | |
| 650 | 7 | |a Liver X Receptors |2 NLM | |
| 650 | 7 | |a 27-hydroxycholesterol |2 NLM | |
| 650 | 7 | |a 6T2NA6P5SQ |2 NLM | |
| 650 | 7 | |a CYP27A1 protein, human |2 NLM | |
| 650 | 7 | |a EC 1.14.15.15 |2 NLM | |
| 650 | 7 | |a Cholestanetriol 26-Monooxygenase |2 NLM | |
| 650 | 7 | |a EC 1.14.15.15 |2 NLM | |
| 700 | 1 | |a Wang, Lawrence |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Adam T |e verfasserin |4 aut | |
| 700 | 1 | |a Han, Chaeyeon |e verfasserin |4 aut | |
| 700 | 1 | |a He, Sisi |e verfasserin |4 aut | |
| 700 | 1 | |a Henn, Madeline A |e verfasserin |4 aut | |
| 700 | 1 | |a Menon, Karan |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Joy J |e verfasserin |4 aut | |
| 700 | 1 | |a Baek, Amy E |e verfasserin |4 aut | |
| 700 | 1 | |a Vardanyan, Anna |e verfasserin |4 aut | |
| 700 | 1 | |a Shahoei, Sayyed Hamed |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Sunghee |e verfasserin |4 aut | |
| 700 | 1 | |a Shapiro, David J |e verfasserin |4 aut | |
| 700 | 1 | |a Nanjappa, Som G |e verfasserin |4 aut | |
| 700 | 1 | |a Nelson, Erik R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Cancer letters |d 1976 |g 493(2020) vom: 28. Nov., Seite 266-283 |w (DE-627)NLM000147273 |x 1872-7980 |7 nnns |
| 773 | 1 | 8 | |g volume:493 |g year:2020 |g day:28 |g month:11 |g pages:266-283 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.canlet.2020.08.020 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 493 |j 2020 |b 28 |c 11 |h 266-283 | ||